Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Company Overview - Teva has been implementing a pivot to growth strategy for the past three years, transitioning from a leading generics company to a world-leading biopharma company, demonstrating significant progress in business setup and financials [3]. Financial Performance - The product AUSTEDO, initially projected by analysts to achieve peak sales of approximately $1.4 billion, is expected to exceed $2 billion this year and reach peak sales of over $3 billion [4]. - Teva has successfully launched UZEDY, a long-acting schizophrenia product, and has driven continued growth of AJOVY, its migraine product, indicating strong performance in innovative product sales [4].